Palouse Capital Management’s Quest Diagnostics DGX Stock Holding History

Palouse Capital Management’s Portfolio DGX Stock Details DGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-1,244	Closed	-$215K	–	105
2021 Q4	$215K	Buy	+1,244	New	+$189K	0.09%	99
2021 Q3	–	Sell	-23,519	Closed	-$3.1M	–	97
2021 Q2	$3.1M	Sell	23,519 -350	-1%	-$45.8K	1.36%	33
2021 Q1	$3.06M	Buy	23,869 +4,145	+21%	+$511K	1.35%	33
2020 Q4	$2.35M	Sell	19,724 -1,968	-9%	-$240K	1.24%	38
2020 Q3	$2.48M	Buy	+21,692	New	+$2.56M	1.39%	34
2020 Q2	–	Sell	-41,685	Closed	-$3.35M	–	76
2020 Q1	$3.35M	Buy	+41,685	New	+$4.32M	1.98%	24

Other funds holding DGX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

DSA

Davis Selected Advisers Tucson, Arizona $21.8B AUM 23.45% 1-Year Est. Return

Grantham, Mayo, Van Otterloo & Co (GMO) Boston, Massachusetts $39.1B AUM 28.69% 1-Year Est. Return

Palouse Capital Management's DGX Position: Q1 2022 in Review

Palouse Capital Management sold out of Quest Diagnostics (DGX) in Q1 2022, closing a stake of 1,244 shares — an estimated $215K sold.

Palouse Capital Management first reported a position in DGX in Q1 2020 and held it in 6 quarters. The position peaked at $3.35M in Q1 2020. 852 funds tracked by Wall St. Rank hold DGX as of Q1 2022.

Palouse Capital Management reported no remaining Quest Diagnostics position as of Q1 2022 after selling out during the quarter.
Palouse Capital Management sold 1,244 Quest Diagnostics shares in Q1 2022, an estimated $215K.
Palouse Capital Management first reported a position in Quest Diagnostics in Q1 2020 and held it in 6 quarters.
Palouse Capital Management's Quest Diagnostics position peaked at $3.35M in Q1 2020.
852 funds tracked by Wall St. Rank held Quest Diagnostics as of Q1 2022.

Based on Palouse Capital Management's 13F filing for Q1 2022, filed 21 Apr 2022.